Inclusion Criteria: 1. Males and females 40-80 years of age 2. Must demonstrate daily cough and significant mucus production 3. Have had a diagnosis of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) for a minimum of two years. (CB is defined clinically as chronic productive cough for 3 months in each of 2 successive years in a patient in whom other causes of productive cough have been excluded) 4. Smoking history of at least 10 pack years 5. Non-smoking for a minimum of 2 months prior to consent and agrees to continue not smoking for the duration of the study Exclusion Criteria: 1. Have had an acute pulmonary infection, exacerbation or pneumonia requiring medical treatment (with antibiotics and/or steroids) within 4 weeks prior of initially planned study bronchoscopy 2. Diagnosis of Asthma 3. You have had any type of transplant procedure 4. Use e-cigarettes, vaping or inhaled substances not prescribed by a physician RejuvenAir® System 5. You are pregnant, nursing, or planning to get pregnant during study * This is a not a complete list of either inclusion or exclusion criteria

- You must be between the ages of 40 and 85
- Willing to have MRI imaging of the brain

Inclusion criteria:
- Between the ages of 18 and 61
- Currently taking an antidepressant
- Currently experiencing symptoms of depression

- Be at least 7 years of age
- Have a history of head trauma, such as concussion

You may be eligible for this study if you:
• Are 18 - 50 years of age
• Suspected chondral damage in the following locations where debridement is indicated:
o Medial femoral condyle
o Lateral femoral condyle
o Trochlea
o Patella
• 1 or more chondral lesion(s) as noted on MRI

Exclusion:
• Previous chondral treatment in the same compartment (prior debridement and lavage performed more than three months prior to baseline are acceptable)
• Pregnant and/or intending to become pregnant during this study period

Inclusion Criteria:
• Between 40 and 75 years of age
• Non-smoking for a minimum of 2 months prior to consent and agrees to not smoke for the duration of the study
• Diagnosis of COPD with 30% ≤ FEV1 <60% of predicted and FEV1/FVC <70% (post-bronchodilator)
• SpO2 of at least 89% on room air at the time of screening
• Has a documented history of having minimally been taking a regular respiratory maintenance medication for at least 12 months at the time of consent; medications will be reviewed by study team
• If you have participated in a formal pulmonary rehabilitation program recently, program completion should have occurred more than 3 months prior to consent; if in a maintenance program, you will agree to continue your current program through your 12-month follow-up visit;
• Additional criteria will be reviewed by the study team

Involvement in this study will last approximately 62 months.

-Ages 18 to 60.
-Patient’s body mass index (BMI) is <35 kg/m2
-Patient has a symptomatic lesion of the femoral condyle (medial and/or lateral) or femoral trochlea that is between 1--6 cm2 on screening images confirmed by the independent radiologist
-Patient is using only nonsteroidal anti-inflammatory drugs or acetaminophen/paracetamol during the month before signing the informed consent form to treat knee pain
-Patient is willing to use other pain medication rather than NSAIDS for 6 months post-surgery (e.g. acetaminophen, or narcotic analgesics, if prescribed). Post-surgical use of aspirin for clot prevention is acceptable.
-Patient is willing to restrict pain medication after 6 months post-surgery to NSAIDs or acetaminophen/paracetamol only through the end of the trial
-No history of previous microfracture or other cartilage repair procedure on study knee
-Not currently pregnant or expecting to become pregnant in the next 12 months
-No diagnosis of advanced osteoarthritis

Inclusion Criteria:
--Ages 18-65
•Little response to conservative treatment (non-operative treatments such as physical therapy, weight loss)
•Single articular cartilage lesion on the femoral condyle (round projection at the end of the femur) 2-6 cm2
•BMI less than 40

Exclusion Criteria:
•Instability of the knee joint
•Arthritis
•Autoimmune disease
•Immune suppression
•Prior surgical treatment using mosaicplasty, autologous chondrocyte implantation and/or microfracture (debridement and lavage are acceptable beyond three months from baseline)
•Bone disease
•Any degenerative muscular, connective tissue or neurological condition or other disease process that would interfere with healing or the evaluation of outcome measures.

Eligibility Criteria
• 18 years of age or older
• Subchondral bone defect(s) in the hip (femoral head, femoral neck and/or acetabulum) has been confirmed via MRI or x-ray.
• Other requirements reviewed by the physician.

Exclusion Criteria:
• Collapse of the subchondral bone

Inclusion Criteria:

- You are scheduled for a new implant or IPG device replacement surgery with a market-released Abbott DBS system within 3 months

Exclusion Criteria:

- You are currently enrolled or plan to enroll in another study that may alter the results of this clinical investigation
- You have another disease, conditions, or other medical, social, or psychological conditions that could limit the your ability to participate in the clinical investigation or to satisfy follow-up requirements

You may eligible for this study if you are:
• 18 years of age or older
• Currently unemployed or laid off
• Be considered high risk if infected with COVID-19 (e.g., being 65 or older or having an underlying health condition).
• Have NOT had a positive COVID-19 test result
• Do NOT have an immunity to COVID-19

Eligibility Criteria:

- Must be 18 and 35 years of age
- Have normal or corrected to normal vision